Who are OPC-1085EL ophthalmic solution's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): DIPHENHYDRAMINE CITRATE, Nevanac, Xibrom, Excedrin Extra Strength Pain Reliever, Mobic, Celebrex.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/opc-1085el-ophthalmic-solution.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

OPC-1085EL ophthalmic solution — Competitive Intelligence Brief

OPC-1085EL ophthalmic solution (OPC-1085EL ophthalmic solution) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: anti-inflammatory. Area: Ophthalmology.

phase 3 anti-inflammatory Ophthalmology Small molecule Live · refreshed every 30 min

Target snapshot

OPC-1085EL ophthalmic solution (OPC-1085EL ophthalmic solution) — Otsuka Pharmaceutical Co., Ltd.. OPC-1085EL ophthalmic solution is an anti-inflammatory agent.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
OPC-1085EL ophthalmic solution TARGET	OPC-1085EL ophthalmic solution	Otsuka Pharmaceutical Co., Ltd.	phase 3	anti-inflammatory
DIPHENHYDRAMINE CITRATE	DIPHENHYDRAMINE CITRATE		marketed	Nonsteroidal Anti-inflammatory Drug [EPC]		2005-01-01
Nevanac	NEPAFENAC	Harrow Health	marketed	Nonsteroidal Anti-inflammatory Drug [EPC]	Prostaglandin G/H synthase 2	2005-01-01
Xibrom	BROMFENAC	Bausch Health	marketed	Nonsteroidal Anti-inflammatory Drug	Prostaglandin G/H synthase 2	2005-01-01
Excedrin Extra Strength Pain Reliever	NSAID	Haleon Us Holdings	marketed	Nonsteroidal Anti-inflammatory Drug [EPC]	Cyclooxygenase	2004-01-01
Mobic	MELOXICAM	Boehringer Ingelheim	marketed	Nonsteroidal Anti-inflammatory Drug [EPC]	Prostaglandin G/H synthase 2	2000-01-01
Celebrex	celecoxib	Pfizer Inc. (originally Searle/Pharmacia)	marketed	Nonsteroidal Anti-inflammatory Drug [EPC]	COX-2	1998-12-31

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

2030-05-26 — Mobic · 10709713 · Method of Use · US
2030-05-26 — Mobic · 9974746 · Formulation · US
2030-05-26 — Mobic · 11253478 · Formulation · US
2030-08-31 — Mobic · 8545879 · Formulation · US
2033-03-31 — Mobic · 9526734 · Formulation · US
2035-03-31 — Mobic · 9808468 · Method of Use · US
2035-03-31 — Mobic · 9649318 · Formulation · US
2036-05-27 — Celebrex · 10722456 · Formulation · US
2036-05-27 — Celebrex · 10376527 · Formulation · US
2036-05-27 — Celebrex · 9795620 · Formulation · US
2036-05-27 — Celebrex · 9949990 · Formulation · US
2036-05-27 — Celebrex · 10799517 · Formulation · US
2036-05-27 — Celebrex · 9572819 · Formulation · US
2039-03-08 — Mobic · 11458145 · Method of Use · US
2039-03-08 — Mobic · 10881663 · Method of Use · US
2040-07-19 — Mobic · 12059423 · Compound · US
2041-07-31 — Mobic · 12263176 · Formulation · US

Sponsor landscape (anti-inflammatory class)

Otsuka Pharmaceutical Co., Ltd. · 1 drug in this class
Santen Inc. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). OPC-1085EL ophthalmic solution — Competitive Intelligence Brief. https://druglandscape.com/ci/opc-1085el-ophthalmic-solution. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab